Critical shortage in BCG immunotherapy: How did we get here and where will it take us?
- Author(s)
- Harvey, M; Chislett, B; Perera, M; Lawrentschuk, N; Bolton, D; Jack, G;
- Details
- Publication Year 2022-01,Volume 40,Issue #1,Page 1-3
- Journal Title
- Urologic Oncology: Seminars and Original Investigations
- Publication Type
- Commentary
- Abstract
- Intravesical Bacillus Calmette-Guerin vaccine, one of the most successful bio-therapies to date, has been the gold standard treatment for non-muscle invasive bladder cancer for 44 years. International shortages have necessitated rationing this life-saving medication with deleterious effects on the primary treatment of high-grade non-muscle invasive bladder cancer. Understanding the history of intravesical Bacillus Calmette-Guerin gives us insight into the current shortages and future perspectives for novel immunotherapy opportunities against this deadly disease.
- Keywords
- Adjuvants, Immunologic/*supply & distribution/therapeutic use; BCG Vaccine/*supply & distribution/therapeutic use; Humans; Immunotherapy; Urinary Bladder Neoplasms/drug therapy; Bacillus Calmette-Guerin vaccine; Bladder cancer; Tuberculosis
- Department(s)
- Surgical Oncology
- PubMed ID
- 34750053
- Publisher's Version
- https://doi.org/10.1016/j.urolonc.2021.09.022
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-11-01 04:30:28
Last Modified: 2024-11-01 04:31:35